新西兰扩大对黑色素瘤免疫治疗的资金. NZ expands funding for melanoma immunotherapy treatments.

新西兰的健康机构 Pharmac 在 2026 年 5 月宣布将扩大对两种黑色素瘤治疗药物 nivolumab 和 ipilimumab 的资金. New Zealand's health agency Pharmac announced in May 2026 it will expand funding for two melanoma treatments, nivolumab and ipilimumab. 这一决定将允许在手术前接受免疫治疗的晚期,可以通过手术切除黑色素瘤患者. This decision will allow patients with advanced, surgically removable melanoma to receive immunotherapy prior to surgery. 治疗的目的是显著缩小瘤,从而减少进一步癌症治疗的需要并减轻医院瘤中心的压力. The treatment aims to shrink tumors significantly, potentially reducing the need for further cancer therapy and easing pressure on hospital oncology centers.